Aerosol gemcitabine: Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 4, 2010, Pages 197-206

  Rodriguez, Carlos O ^a   Crabbs, Torrie A ^a   Wilson, Dennis W ^a   Cannan, Virginia A ^a   Skorupski, Katherine A ^a   Gordon, Nancy ^a   Koshkina, Nadya ^a   Kleinerman, Eugenie ^a   Anderson, Peter M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

aerosol chemotherapy; dog model; gemcitabine; relapsed osteosarcoma

Indexed keywords

FAS ANTIGEN; GEMCITABINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTERIAL GAS; ARTICLE; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG METASTASIS; MALE; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; TUMOR MODEL;

AEROSOLS; ANIMALS; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; DEOXYCYTIDINE; DOGS; FAS LIGAND PROTEIN; LUNG NEOPLASMS; OSTEOSARCOMA;

EID: 77955449671     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0773     Document Type: Article

References (57)

1. Jongeward SJ: Primary bone tumors. Vet Clin North Am Small Anim Pract. 1985;15:609-641.
2. Herzog CE: Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol. 2005; 27:215 218.
3. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and=or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
4. Anderson P: Osteosarcoma relapse: expect the worst, but hope for the best. Pediatr Blood Cancer. 2006;47:231.
5. Crompton BD, Goldsby RE, Weinberg VK, Feren R, ODonnell RJ, Ablin AR: Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer. 2006;47:255-259.
6. Hawkins DS, Arndt CA: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98:2447-2456.
7. Mauldin GN, Matus RE, Withrow SJ, Patnaik AK: Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med. 1988;2:177-180.
8. Shapiro W, Fossum TW, Kitchell BE, Couto CG, Theilen GH: Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc. 1988;192:507-511.
9. Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc. 1992;200:995-999.
10. Berg J: Canine osteosarcoma: amputation and chemotherapy. Vet Clin North Am Small Anim Pract. 1996;26:111-121.
11. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kruth SA, Klein MK, Klausner J, Norris AM, McCaw D, Straw RC, Withrow SJ: Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med. 1996;10:76-81.
12. Kraegel SA, Madewell BR, Simonson E, Gregory CR: Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc. 1991;199:1057-1059.
13. Madewell BR, Leighton RL, Theilen GH: Amputation and doxorubicin for treatment of canine and feline osteogenic sarcoma. Eur J Cancer. 1978;14:287-293.
14. Thompson JP, Fugent MJ: Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc. 1992;200:531-533.
15. Berg J, Weinstein MJ, Springfield DS, Rand WM: Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc. 1995;206:1555-1560.
16. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vail DM, Morrison WB, McGee M, Dickson K: Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med. 1991;5: 205-210.
17. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 20,20-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110-6117.
18. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821-1826.
19. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V: Gemcitabine in the treatment of refractory Hodgkins disease: results of a multicenter phase II study. J Clin Oncol. 2000;18:2615-2619.
20. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S: Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18: 2603-2606.
21. Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J, Khayat D, Rivelles N: Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol. 2000;18:2545-2552.
22. van Moorsel CJ, Peters GJ, Pinedo HM: Gemcitabine: Future prospects of single-agent and combination studies. Oncologist. 1997;2:127-134.
23. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002;94:3225-3229.
24. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000;45:177-181.
25. Gandhi V, Plunkett W, Du M, Ayres M, Estey EH: Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002;20:665-673.
26. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992;10:406-413.
27. Rizzieri DA, Bass AJ, Rosner GL, Gockerman JP, DeCastro CM, Petros WP, Adams DJ, Laughlin MJ, Davis P, Foster T, Jacobson R, Hurwitz H, Moore JO: Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol. 2002;20: 674-679.
28. Jones PD, de Lorimier LP, Kitchell BE, Losonsky JM: Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc. 2003;39: 463-467.
29. Kosarek CE, Kisseberth WC, Gallant SL, Couto CG: Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med. 2005;19:81-86.
30. LeBlanc AK, LaDue TA, Turrel JM, Klein MK: Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound. 2004;45:466-470.
31. Turner AI, Hahn KA, Rusk A, Gamblin RM, Cosgrove SB, Griffice K, Khanna C: Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med. 2006;20:1384-1388.
32. Freise KJ, Martin-Jimenez T: Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther. 2006;29:147-152.
33. Freise KJ, Martin-Jimenez T: Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J Vet Pharmacol Ther. 2006;29:137-145.
34. Ando T, Ichikawa J, Okamoto A, Tasaka K, Nakao A, Hamada Y: Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res. 2005;23: 964-969.
35. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, Gerss J, Stoffregen C, Boos J: Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs. 2006;17:859-864.
36. Zak D, Styler MJ, Rosenbluth JZ, Brodsky I: Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma. Clin Adv Hematol Oncol. 2005;3:297-299; discussion 300-302.
37. Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, Trotz B, Dubansky SA, Albritton K: Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005;11:6895-6900.
38. Merimsky O, Meller I, Kollender Y, Inbar M: Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer. 1998;34:1296-1297.
39. Merimsky O, Meller I, Kollender Y, Issakov J, Flusser G, Inbar M: Gemcitabine in bone sarcoma resistant to Doxorubicinbased chemotherapy. Sarcoma. 2000;4:7-10.
40. Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113:419-425.
41. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES: Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res. 2007;13:4503-4510.
42. Koshkina NV, Kleinerman ES: Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005;116:458-463.
43. Gagnadoux F, Leblond V, Vecellio L, Hureaux J, Le Pape A, Boisdron-Celle M, Montharu J, Majoral C, Fournier J, Urban T, Diot P, Racineux JL, Lemarié E: Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol. 2006;58:237-244.
44. Khanna C, Hasz DE, Klausner JS, Anderson PM: Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res. 1996;2:721-734.
45. Khanna C, Waldrep JC, Anderson PM, Weischelbaum RW, Hasz DE, Katsanis E, Klausner JS: Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol. 1997;49:960-971.
46. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, Imondi AR, Vail DM: Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res. 1999;5:2653-2659.
47. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V: Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001;7:3258-3262.
48. Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES: Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol. 2005;27:611-615.
49. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES: Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res. 2007;5:991-999.
50. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES: Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res. 2004;10:8114-8119.
51. Worth LL, Lafleur EA, Jia SF, Kleinerman ES: Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep. 2002;9:823-827.
52. Rodriguez CO, Jr., Stellrecht CM, Gandhi V: Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003;102:1842-1848.
53. Friesen C, Fulda S, Debatin KM: Cytotoxic drugs and the CD95 pathway. Leukemia. 1999;13:1854-11848
54. Friesen C, Fulda S, Debatin KM: Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ. 1999;6:471-480.
55. Kleinerman ES, Maeda M, Jaffe N: Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:101-107.
56. Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ: Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992;34: 211-220.
57. Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA: Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res. 2007;13:323-330.